Pilot Study of Natalizumab in the Treatment of Patients With Inclusion Body Myositis
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2017
At a glance
- Drugs Natalizumab (Primary)
- Indications Inclusion body myositis
- Focus Adverse reactions; Therapeutic Use
- 08 Feb 2017 Planned primary completion date changed from 1 May 2016 to 1 Nov 2017.
- 08 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Apr 2016 Interim results (n=2) presented at the 68th Annual Meeting of the American Academy of Neurology